Mylan, Orion settle Parkinson's disease drug case

Mylan can launch generic entacapone tablets in April 2013

PITTSBURGH — Generic drug maker Mylan has settled with Orion over a drug used to treat Parkinson's disease, Mylan said Thursday.

The company said it reached a settlement with Orion to resolve patent litigation concerning a generic version of Orion's drug Comtan (entacapone) tablets in the 200-mg strength. The drug is used with levodopa-carbidopa therapy to treat Parkinson's patients who experience signs and symptoms of end-of-dose "wearing off."

Under the agreement, Mylan can launch a generic version of Comtan on April 1, 2013. Other terms of the deal were not disclosed. According to Food and Drug Administration records, the two patents covering Comtan expire in October 2013 and September 2018.

Entacapone tablets in the 200-mg strength had sales of about $104.9 million during the 12-month period that ended in September 2012, according to IMS Health.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

Login or Register to post a comment.